Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,509 Mln
P/E Ratio
--
P/B Ratio
2.57
Industry P/E
--
Debt to Equity
0.09
ROE
-0.45 %
ROCE
-38.66 %
Div. Yield
0 %
Book Value
10.49
EPS
-2.77
CFO
$-228.58 Mln
EBITDA
$-290.88 Mln
Net Profit
$-282.92 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| -43.25 | -9.88 | -33.30 | -39.47 | 5.48 | -- | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| 172.71 | -20.52 | -27.58 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of... atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vera Therapeutics Inc Class A (VERA) stood at $ 656 Mln as on 31-Dec-24
The share price of Vera Therapeutics Inc Class A (VERA) is $24.00 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Vera Therapeutics Inc Class A (VERA) has given a return of 5.48% in the last 3 years.
Vera Therapeutics Inc Class A (VERA) has a market capitalisation of $ 1,509 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Vera Therapeutics Inc Class A (VERA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vera Therapeutics Inc Class A (VERA) and enter the required number of quantities and click on buy to purchase the shares of Vera Therapeutics Inc Class A (VERA).
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
The CEO & director of Dr. Marshall W. Fordyce M.D.. is Vera Therapeutics Inc Class A (VERA), and CFO & Sr. VP is Dr. Marshall W. Fordyce M.D..
There is no promoter pledging in Vera Therapeutics Inc Class A (VERA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Vera Therapeutics Inc. Class A (VERA) | Ratios |
|---|---|
|
Return on equity(%)
|
-44.83
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vera Therapeutics Inc Class A (VERA) was $0 Mln.
$0.59
(
